Surface Oncology 미래 성장

Future 기준 확인 0/6

Surface Oncology은 연간 수입과 매출이 각각 13.8%와 81.8% 증가할 것으로 예상되고 EPS는 연간 16.4%만큼 증가할 것으로 예상됩니다.

주요 정보

13.8%

수익 성장률

16.4%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	81.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	02 Aug 2023

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:QSOA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	10	-84	N/A	N/A	3
12/31/2024	N/A	-92	N/A	N/A	3
12/31/2023	N/A	-92	N/A	N/A	2
6/30/2023	N/A	-93	-84	-84	N/A
3/31/2023	N/A	-90	-60	-59	N/A
12/31/2022	30	-64	-60	-60	N/A
9/30/2022	30	-66	-54	-54	N/A
6/30/2022	31	-63	-50	-50	N/A
3/31/2022	31	-57	-67	-67	N/A
12/31/2021	3	-78	-62	-62	N/A
9/30/2021	90	13	26	26	N/A
6/30/2021	90	17	31	31	N/A
3/31/2021	89	21	27	27	N/A
12/31/2020	126	59	30	30	N/A
9/30/2020	39	-24	-56	-56	N/A
6/30/2020	39	-25	-60	-60	N/A
3/31/2020	40	-28	-58	-57	N/A
12/31/2019	15	-55	-62	-60	N/A
9/30/2019	25	-44	-63	-61	N/A
6/30/2019	26	-44	-61	-58	N/A
3/31/2019	28	-35	-65	-63	N/A
12/31/2018	59	-7	-15	-13	N/A
9/30/2018	52	-18	-15	-14	N/A
6/30/2018	53	-15	-12	-11	N/A
3/31/2018	57	-13	21	22	N/A
12/31/2017	13	-45	-14	-12	N/A
9/30/2017	12	-36	-13	-11	N/A
12/31/2016	7	-17	N/A	41	N/A

애널리스트 미래 성장 예측

수입 대 저축률: QSOA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: QSOA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: QSOA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: QSOA 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: QSOA 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: QSOA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Surface Oncology 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견